Assessment of Mortality-Related Risk Factors and Effective Antimicrobial Regimens for Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa in Patients with Hematological Diseases

Assessment of Mortality-Related Risk Factors and Effective Antimicrobial Regimens for Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa in Patients with Hematological Diseases

2024.03.01
In May 2023, a  study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal ——Frontiers in Cellular and Infection Microbiology. The title of the study is "Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa in patients with hematological diseases". This study emphasizes the importance of identifying high-risk MDR infections and selecting appropriate antibiotic therapy to improve patient survival.
ID Week Commentary | Dr. Junyan Qu: Real-world Efficacy Comparison of CT vs. CZA in Treating MDR-PA Infections

ID Week Commentary | Dr. Junyan Qu: Real-world Efficacy Comparison of CT vs. CZA in Treating MDR-PA Infections

2024.02.19
Multi-drug resistant organisms (MDRO) are commonly found in bacteria such as Enterobacteriaceae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. In recent years, the emergence and spread of MDRO have posed numerous challenges in clinical practice, with limited treatment options being one of the thorny issues. Beta-lactamase inhibitor combinations are essential in the clinical management of MDRO infections, among which Ceftolozane-Tazobactam (CT) and Ceftazidime-Avibactam (CZA) are frontline drugs for treating Multi-drug Resistant Pseudomonas aeruginosa (MDR-PA) infections. However, there is a lack of sufficient research data comparing the efficacy of these two drugs. At the recent IDWeek 2023 held in the United States, researchers presented a multicenter observational study (Abstract No: 1109) that compared the efficacy of CT and CZA in treating MDR-PA-induced bacteremia or pneumonia. " Infectious Disease Frontline" invited Dr. Junyan Qu, from West China Hospital of Sichuan University, to introduce and comment on this study.